MX2021013070A - Farmaco terapeutico para discinesia. - Google Patents
Farmaco terapeutico para discinesia.Info
- Publication number
- MX2021013070A MX2021013070A MX2021013070A MX2021013070A MX2021013070A MX 2021013070 A MX2021013070 A MX 2021013070A MX 2021013070 A MX2021013070 A MX 2021013070A MX 2021013070 A MX2021013070 A MX 2021013070A MX 2021013070 A MX2021013070 A MX 2021013070A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic drug
- dyskinesia
- levodopa
- tandospirone
- parkinson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/395,531 US10758535B1 (en) | 2019-04-26 | 2019-04-26 | Therapeutic drug for dyskinesia |
| PCT/JP2020/017652 WO2020218487A1 (en) | 2019-04-26 | 2020-04-24 | Therapeutic drug for dyskinesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013070A true MX2021013070A (es) | 2021-11-17 |
Family
ID=72241591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013070A MX2021013070A (es) | 2019-04-26 | 2020-04-24 | Farmaco terapeutico para discinesia. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10758535B1 (enExample) |
| EP (1) | EP3958972A4 (enExample) |
| JP (2) | JP7695891B2 (enExample) |
| KR (1) | KR20220004640A (enExample) |
| CN (1) | CN113646045A (enExample) |
| AU (1) | AU2020260895A1 (enExample) |
| BR (1) | BR112021021184A8 (enExample) |
| CA (1) | CA3137400A1 (enExample) |
| EA (1) | EA202192928A1 (enExample) |
| MX (1) | MX2021013070A (enExample) |
| PH (1) | PH12021552681A1 (enExample) |
| SG (1) | SG11202111852TA (enExample) |
| WO (1) | WO2020218487A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11559525B2 (en) * | 2019-04-26 | 2023-01-24 | Sumitomo Pharma Co., Ltd. | Therapeutic drug for dyskinesia |
| CA3168199A1 (en) | 2020-02-19 | 2021-08-26 | Eri ICHIBAYASHI | Transdermal absorption preparation |
| JPWO2022045336A1 (enExample) * | 2020-08-31 | 2022-03-03 | ||
| CA3221728A1 (en) * | 2021-06-30 | 2023-01-05 | Grace S. LIANG | Valbenazine for use in the treatment of dyskinesia due to cerebral palsy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507303A (en) | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| JPH11228414A (ja) | 1998-02-06 | 1999-08-24 | Sumitomo Pharmaceut Co Ltd | タンドスピロン経皮剤 |
| ES2716404T3 (es) * | 2002-01-28 | 2019-06-12 | Kyowa Hakko Kogyo Kk | Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento |
| WO2005117886A1 (ja) | 2004-06-01 | 2005-12-15 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
| ATE413166T1 (de) | 2004-11-22 | 2008-11-15 | Hisamitsu Pharmaceutical Co | Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff |
| JP4873871B2 (ja) | 2005-02-28 | 2012-02-08 | 久光製薬株式会社 | 粘着剤及び貼付剤 |
| WO2008044336A1 (en) | 2006-10-11 | 2008-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Crystal-containing adhesive preparation |
| EP2729176A1 (en) | 2011-07-05 | 2014-05-14 | Contera Pharma APS | The use of serotonin receptor agonists for treatment of movement disorders |
| MY169068A (en) | 2012-04-18 | 2019-02-12 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| EP3897641B1 (en) * | 2018-12-20 | 2023-11-15 | Contera Pharma A/S | Treatment of movement disorders |
-
2019
- 2019-04-26 US US16/395,531 patent/US10758535B1/en active Active
-
2020
- 2020-04-22 US US16/855,213 patent/US20210060015A1/en not_active Abandoned
- 2020-04-24 CN CN202080029464.9A patent/CN113646045A/zh active Pending
- 2020-04-24 BR BR112021021184A patent/BR112021021184A8/pt not_active Application Discontinuation
- 2020-04-24 US US17/606,394 patent/US20220193075A1/en not_active Abandoned
- 2020-04-24 JP JP2021561833A patent/JP7695891B2/ja active Active
- 2020-04-24 MX MX2021013070A patent/MX2021013070A/es unknown
- 2020-04-24 SG SG11202111852TA patent/SG11202111852TA/en unknown
- 2020-04-24 EP EP20794266.5A patent/EP3958972A4/en active Pending
- 2020-04-24 CA CA3137400A patent/CA3137400A1/en active Pending
- 2020-04-24 WO PCT/JP2020/017652 patent/WO2020218487A1/en not_active Ceased
- 2020-04-24 KR KR1020217034115A patent/KR20220004640A/ko not_active Withdrawn
- 2020-04-24 PH PH1/2021/552681A patent/PH12021552681A1/en unknown
- 2020-04-24 EA EA202192928A patent/EA202192928A1/ru unknown
- 2020-04-24 AU AU2020260895A patent/AU2020260895A1/en not_active Abandoned
-
2025
- 2025-02-04 JP JP2025017181A patent/JP2025072496A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020218487A1 (en) | 2020-10-29 |
| EP3958972A1 (en) | 2022-03-02 |
| KR20220004640A (ko) | 2022-01-11 |
| EP3958972A4 (en) | 2023-01-04 |
| AU2020260895A1 (en) | 2021-12-23 |
| JP2022529661A (ja) | 2022-06-23 |
| EA202192928A1 (ru) | 2022-02-07 |
| JP7695891B2 (ja) | 2025-06-19 |
| SG11202111852TA (en) | 2021-11-29 |
| CA3137400A1 (en) | 2020-10-29 |
| BR112021021184A2 (enExample) | 2021-12-14 |
| US20220193075A1 (en) | 2022-06-23 |
| US20210060015A1 (en) | 2021-03-04 |
| US10758535B1 (en) | 2020-09-01 |
| JP2025072496A (ja) | 2025-05-09 |
| BR112021021184A8 (pt) | 2023-02-28 |
| CN113646045A (zh) | 2021-11-12 |
| PH12021552681A1 (en) | 2022-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003091A1 (es) | Terapia de combinación. | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| MX2017014804A (es) | Composiciones farmaceuticas topicas. | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| EP4306524A3 (en) | Lymphatic system-directing lipid prodrugs | |
| BR112014030813A2 (pt) | tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson | |
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| EP4464378A3 (en) | Leucine, acetyl leucine, and related analogs for treating disease | |
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| CO2022000016A2 (es) | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd) | |
| AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX350195B (es) | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| ZA202100604B (en) | Methods to reduce complications of intra-articular steroid | |
| AR111464A1 (es) | Terapia combinada para el tratamiento de infecciones virales | |
| JP2019529569A5 (enExample) | ||
| FI3426237T3 (fi) | Menetelmä aivojen atrofian hoitamiseksi | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. | |
| WO2022025785A8 (ru) | Фармацевтическая композиция, включающая мемантин и цитиколин | |
| AR128566A1 (es) | Combinaciones de fármacos y métodos para tratar el cáncer de ovario | |
| BR112014001538A2 (pt) | composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para tratamento de doenças retinais | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |